Home - Ionis Pharmaceuticals

News

July 11, 2018

Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union

July 5, 2018

New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

June 18, 2018

Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer

June 5, 2018

Ionis Closes Strategic Collaboration with Biogen to Develop Drugs for a Broad Range of Neurological Diseases

Latest Updates

Exciting times $ions https://t.co/m9zgbk1Kmd

New #ALS therapy in #clinicaltrials—drug extends survival, reverses some neuromuscular damage in animals @WUSTLmedschool @jclinicalinvest https://t.co/Vuxp9piCrz

Spotlight

Ionis Pharmaceuticals Publishes Paper on Growth of RNA-targeted Therapeutics in Cell Metabolism

Clinical Trials

We have numerous ongoing clinical trials designed to evaluate our drugs in a variety of health conditions. More »

Events

10-08-2018 - 10-10-2018

Ionis Pharmaceuticals, Nature Structural & Molecular Biology, Nature Biotechnology & Nature Medicine present RNA at the Bench and Bedside